anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The efficacy of topotecan hydrochloride was evaluated in 426 patients with recurrent or progressive small cell lung cancer (SCLC) in a randomized, comparative trial and in 3 single-arm trials. 

Randomized Comparative Trial

In a randomized, comparative trial, 211 patients were randomized 1:1 to receive topotecan hydrochloride (1.5 mg/m2 once daily intravenously for 5 days starting on Day 1 of a 21-day cycle) or CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 mg/m2, vincristine 2 mg administered sequentially on Day 1 of a 21-day cycle). All patients were considered sensitive to first-line chemotherapy (responders who then subsequently progressed greater than or equal to 60 days after completion of first-line therapy). A total of 77% of patients treated with topotecan hydrochloride and 79% of patients treated with CAV received platinum/etoposide with or without other agents as first-line chemotherapy. The efficacy outcome measures were overall response rate, response duration, time to progression or OS. 

The results of the trial did not show statistically significant improvements in response rate, response duration, time to progression, or OS as shown in Table 5. 

The median time to response was similar in both arms: topotecan hydrochloride, 6 weeks (2.4 weeks to 3.6 months) versus CAV, 6 weeks (5.1 weeks to 4.2 months). 

Changes on a disease-related symptom scale are presented in Table 6. It should be noted that not all patients had all symptoms, nor did all patients respond to all questions. Each symptom was rated on a 4-category scale with an improvement defined as a change in 1 category from baseline sustained over 2 courses. Limitations in interpretation of the rating scale and responses preclude formal statistical analysis. 

Single-Arm Trials

Topotecan hydrochloride was also studied in 3 open-label, non-comparative trials (Studies 014, 092 and 053) in a total of 319 patients with recurrent or progressive SCLC after treatment with first-line chemotherapy. In all 3 trials, patients were stratified as either sensitive (responders who then subsequently progressed greater than or equal to 90 days after completion of first-line therapy) or refractory (no response to first-line chemotherapy or who responded to first-line therapy and then progressed within 90 days of completing first-line therapy). Response rates ranged from 11% to 31% for sensitive patients and 2% to 7% for refractory patients. Median time to progression and median survival were similar in all 3 trials and the comparative trial.
SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
PURPOSE OF REVIEW: There has been a rapid increase in silicosis cases, particularly related to artificial stone. The key to management is avoidance of silica exposure. Despite this, many develop progressive disease and there are no routinely recommended treatments. This review provides a summary of the literature pertaining to pharmacological therapies for silicosis and examines the plausibility of success of such treatments given the disease pathogenesis.
RECENT FINDINGS: In-vitro and in-vivo models demonstrate potential efficacy for drugs, which target inflammasomes, cytokines, effector cells, fibrosis, autophagy, and oxidation.
SUMMARY: There is some evidence for potential therapeutic targets in silicosis but limited translation into human studies. Treatment of silicosis likely requires a multimodal approach, and there is considerable cross-talk between pathways; agents that modulate both inflammation, fibrosis, autophagy, and ROS production are likely to be most efficacious.
Innate immunity is not only the first line of host defense against microbial infections but is also crucial for the host responses against a variety of noxious stimuli. Z-DNA binding protein 1 (ZBP1) is a cytosolic nucleic acid sensor that can induce inflammatory cell death in both immune and nonimmune cells upon sensing of incursive virus-derived Z-form nucleic acids and self-nucleic acids via its Zα domain. Mechanistically, aberrantly expressed or activated ZBP1 induced by pathogens or noxious stimuli enables recruitment of TANK binding kinase 1 (TBK1), interferon regulatory factor 3 (IRF3), receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 to drive type I interferon (IFN-I) responses and activation of nuclear factor kappa B (NF-κB) signaling. Meanwhile, ZBP1 promotes the assembly of ZBP1- and absent in melanoma 2 (AIM2)-PANoptosome, which ultimately triggers PANoptosis through caspase 3-mediated apoptosis, mixed lineage kinase domain like pseudokinase (MLKL)-mediated necroptosis, and gasdermin D (GSDMD)-mediated pyroptosis. In response to damaged mitochondrial DNA, ZBP1 can interact with cyclic GMP-AMP synthase to augment IFN-I responses but inhibits toll like receptor 9-mediated inflammatory responses. This review summarizes the structure and expression pattern of ZBP1, discusses its roles in human diseases through immune-dependent (e.g., the production of IFN-I and pro-inflammatory cytokines) and -independent (e.g., the activation of cell death) functions, and highlights the attractive prospect of manipulating ZBP1 as a promising therapeutic target in diseases.
Two multicenter, randomized, investigator-blind, active-controlled trials were conducted in 1038 subjects 6 months of age and older with head lice infestation. A total of 552 subjects were treated with NATROBA. For the evaluation of efficacy, the youngest subject from each household was considered to be the primary subject of the household, and other members in the household were enrolled in the study as secondary subjects and evaluated for all safety parameters.

In Study 1, 91 primary subjects were randomized to NATROBA, and 89 primary subjects were randomized to permethrin 1%. In Study 2, 83 and 84 primary subjects were randomized to NATROBA and permethrin 1%, respectively.

In both trials, all subjects who were treated on Day 0 returned for efficacy evaluation at Day 7. Subjects with live lice present at Day 7 received a second treatment. Subjects who were lice free on Day 7 were to return on Day 14 for evaluation. Subjects with live lice and who received a second treatment were to return on Days 14 and 21.

Efficacy was assessed as the proportion of primary subjects who were free of live lice 14 days after the final treatment. Table 3 contains the proportion of primary subjects who were free of live lice in each of the two trials.
Described are controlled, time-release microparticulate active and bioactive compositions (including perfuming compositions) for targeted delivery to services such as skin, hair and fabric and the environment proximate thereto, where the active and bioactive materials have a calculated log10P values of between 1 and 8 (P being the n-octanol-water partition coefficient).  Such compositions include the active or bioactive material in single phase, solid solution in a wax or polymer matrix also having coated thereon and/or containing a compatible surfactant.  Also described are processes and apparatus for preparing such compositions and processes for using same.  Furthermore, certain component(s) of the aforementioned compositions in combination with one another are novel, and other components have novel uses in increasing fragrance substantivity.      Also described is fragrance diffusion evaluation apparatus for testing the diffusivity, odor character and odor intensity of a fragrance material and a process for using same.  The apparatus includes at least one hollow container means having a test sample suspended therein, air flow means for passing air through the inside of the container means and an exit port for the air flow where the intensity and aroma character are measured as a function of time and as a function of temperature.  The sample is weighed initially and at time intervals while the air is flowing through the cylinders at a fixed or variable rate.
Nasal septoplasty is a surgery procedure which needs to have decrease the bleeding during the surgery for the visibility of surgical site.And postoperative pain is very usual after the surgery, so an effective postoperative analgesia procedure reduces the complications and helps to be discharged earlier from the hospital. An alpha 2 agonist Dexmedetomidine has an analgesic effect and vasoconstructive effect on the periferal blood vessels. Our hypothesis was dexmedetomidine makes a better surgecal conditions during the surgery and reduce the postoperative analgesic consumption. We administered the infiltrated dexmedetomidine or lidocaine plus adrenaline to the both side of the nasal septum 10 minutes before the surgery. Bleeding scores (Fromm and Boezaart Bleeding Scores) were recorded during the surgery. And postoperative analgesic consumptions were recorded in first 24 hours after the surgery.
The present invention relates to a peptide containing five to twenty amino acids, particularly to a ganoderma polysaccharide protein G1-PP extracted from ganoderma. Ganoderma is used as raw material precursors for extracting extraction liquid. After the extraction liquid is concentrated, polysaccharide proteins with high molecular weight are trapped by ultrafiltration or dialysis so that the peptide is obtained. The present invention also relates to a preparation method of the ganoderma polysaccharide protein for industrialized production, and the applications of the ganoderma polysaccharide protein G1-PP to the preparation of antitumor medicine. The present invention can be used for obtaining the ganoderma polysaccharide protein with high molecular weight and medicinal value, and provides a method for preparing a macromolecule ganoderma polysaccharide protein for industrialized production. The preparation method has the advantages of low cost, high extraction rate and high extraction purity. The obtained ganoderma polysaccharide protein can restrain the growth of tumors by restraining the neogenesis of tumor blood vessels and restraining the invasion of cancer cells, and the restriction effect is good. The obtained ganoderma polysaccharide protein is novel antitumor medicine.
ABSTRACT OF THE DISCLOSURE             An epinephrine-containing solution useful in cata-ract surgery in provided by a sulfite or antioxidant-free epinephrine solution.  Before use, the sulfite or antioxidant-free epinephrine solution is contained in an ampule or similar airtight container under a blanket of oxygen-free nitrogen gas. Suitable sulfite or anti-oxidant-free epinephrine solution include a sterile, aqueous epinephrine solution wherein each mL thereof contains epinephrine in the amount 1.0 mg, hydrochloric acid in the amount 0.0005 mL and sodium chloride in the amount about 9.0 mg to render said solution substantial-ly isotonic, the solution having been adjusted to a pH of 7.0 ? 0.1 with sodium citrate and/or citric acid.      Another useful epinephrine solution contains per mL epinephrine  in the amount 1.0 mg, hydrochloric acid in the amount 0.0005 mL, sodium chloride in the amount about 9.0 mg, the pH of said solution having been ad-justed to a value in the range 2.2-5.0 with sodium hydroxide and/or hydrochloric acid.   Still another useful epinephrine-containing solution has the composi-tion per mL epinephrine in the amount 1.0 mg, hydrochloro-ric acid in the amount 0.0005 mL, the remainder being sterile or bacteriostatic water, the pH of said solution having been adjusted to a value in the range 2.2-5.0 with sodium hydroxide and/or hydrochloric acid.
Early rates of successful recanalization (SR) of distal vessel occlusions (DVO) following intravenous thrombolysis (IVT) between alteplase (ALT) and tenecteplase (TNK) are poorly known.

From March 2016 to February 2020, consecutive stroke patients hospitalized in the stroke unit of the Sud-Francilien Hospital with DVO identified on baseline MRI and suitable for IVT but not for mechanical thrombectomy will be included. In our stroke unit, patients were treated with ALT, 0.9 mg/kg from March 2016 to February 2018 and then with TNK, 0.25 mg/kg from March 2018 to December 2023. MRI was controlled 1-2 hours within IVT (MRI-2). Early recanalization was assessed on an adapted Arterial Occlusion Lesion (AOL) scale, SR being defined as AOL 2/3 scores on MRI-2. The rate reduction of thrombus length (TL) when thrombus persisted, the IVT response threshold of TL and the infarct size evolution were also assessed. In the present study, the investigators sought to compare early rates of SR between the two lytics, based on a retrospective analysis of magnetic resonance imaging (MRI) performed early after IVT.
Vector comprises (1) a promoter and operator sequence from lambda bacteriophage, (2) a sequence coding for a hybrid ribosome binding site and (3) an interferon-coding sequence. Esp. (1) is the PL-OL sequence and (2) may code for mature human interferon, human leucocyte interferon or human fibroblast interferon. Component (2) is pref. a modified lambda bacteriophage sequence and typically for mature interferon, has formula GCAACTGACAGGAGAA TTC. Pref. the vector also contains a mutant cI repressorgen from lambda bacteriophage coding for a temp. sensitive repressor protein.
Life expectancy is continuously increasing in Italy. Aging is generally linked to adaptive modifications of organs and systems that reduce the functional reserve and increase the vulnerability to disease and addiction. This framework constitutes the condition of "frailty", which is associated to an increased risk of multiple adverse events as falls, fractures, disability, institutionalisation and death. To reduce the burden of disability and diseases affecting the quality of life of the elderly and, at the same time weighs heavily on health costs, a high level of managerial efficiency has to be achieved, planning the necessary health and care services and implementing measures to prevent disability in the fragile elderly. Indeed a strongly expanding area of gerontological and geriatric research is focusing on successful aging, that is characterised by a low probability of diseases and related disabilities, by a high level of physical and cognitive functionality and by an active social involvement in daily life. For this reason the project is based on the implementation of a validated system of comprehensive geriatric assessment able to provide detailed measures of the different possible interactions among risk factors. The study aimed at the descriptive-epidemiological collection of the health conditions of older in-patients at the different INRCA research hospitals (Italy). The data set will include personal data, information from the comprehensive geriatric assessment, clinical-care, biological and diagnostic data, collected routinely as well as ad hoc during hospitalisation. Moreover, a blood sample will be taken to performing biomarkers and genetic analyses.
PROBLEM TO BE SOLVED: To obtain an external preparation for skin, having excellent preventing and improving effects on skin roughness, not having stickiness and exhibiting an excellent touch. SOLUTION: This preparation for skin contains 0.01-20wt.% of a UV light absorbent and 0.01-30wt.% of a low mol. wt. betaine. One or more kinds of compounds such as para-aminobenzoic acid are arbitrarily used as the UV light absorbent, and a quaternary ammonium salt of the formula [R<1> , R<2> , R<3> are each a 1-6 alkyl; (n) is 0 or a positive integer; wherein the number of the carbon atoms of the R<1> -R<3> and (n) are totally <=8] is preferable as the low mol. wt. betaine. The preparation further contains various kinds of known additives, and is prepared in the forms of an aqueous solution preparation, an emulsion, a powdery preparation, an oily preparation, a gel, an ointment, a water-oil system two-layered preparation, a water-oil-powder system three- layered preparation, etc.  The external preparation exhibits an excellent skin roughness-improving effect due to the synergistic effect of both the ingredients, expresses a non-tacky, refreshing touch, is not powdery, and is good in usability.
PCT No. PCT/DE94/00022 Sec. 371 Date Sep. 29, 1995 Sec. 102(e) Date Sep. 29, 1995 PCT Filed Jan. 12, 1994 PCT Pub. No. WO94/16081 PCT Pub. Date Jul. 21, 1994The present invention is relative to a method for the obtention of native domains of viral membrane proteins, especially of native, that is, oligomeric and glycosylated ectodomains of the surface protein gp160 of the human immunodeficiency virus HIV, the causative agent of AIDS (acquired immune deficiency syndrome), as well as the native protein domains themselves obtained by this method, especially native ectodomains of the env glycoprotein of HIV whose monomers exhibit an electrophoretic mobility of approximately 140 kD as well as their use as vaccine, especially as vaccine against HIV. A nucleotide sequence coding for a recognition sequence for protein-splitting enzymes is inserted at a suitable site into the gene coding for the precursor protein of the protein domain to be obtained. After expression of the gene mutant in eukaryotic cells a digestion with a suitable enzyme is carried out and the protein domain to be obtained is subsequently purified.
Oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users 17. This effect has been shown to be directly related to estrogen dose 65. Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents 17, 66. However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose 67. Because of these demonstrated effects, prediabetic and diabetic women in particular should be carefully monitored while taking oral contraceptives. 

A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a  and 1d), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 

In clinical studies with norgestimate and ethinyl estradiol tablets there were no clinically significant changes in fasting blood glucose levels. No statistically significant changes in mean fasting blood glucose levels were observed over 24 cycles of use. Glucose tolerance tests showed minimal, clinically insignificant changes from baseline to cycles 3, 12, and 24.
This study is designed to test a novel technology to examine early changes in the lung in hopes of identifying patients who may be at risk for radiation pneumonitis. Eligible subjects will undergo standard of care treatment with the use of the Varian TrueBeam system for radiation therapy of a cancer lesion in the chest. The imaging data acquired as part of usual standard of care for these patients is a pre-treatment 4D planning CT scan, and a daily cone beam CT at each radiation treatment visit. We will also obtain a series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions. This study will compare lung function data generated by applying High Fidelity Functional Lung Imaging (HFFLI) software to 4D CT, cone beam CT, and fluoroscopic images of the lungs breathing to determine the degree of correlation between data generated from different imaging modalities. The study is open to adults over the age of 18, at any stage of cancer.
Media and methods for securely providing third-party applications, such as health based service applications, with electronic medical records (EMRs), or discrete information therein, of an individual is provided. To facilitate the secure transfer of medical records, a universal security manager is described. The universal security manager may act as an intermediary between a healthcare service facility, such as a hospital, and the third-party application. A secure link for transferring EMRs from the healthcare service facility to the universal security manager may be established using a secure linking code. The third-party application may be validated as a trusted third-party application by the universal security manager based on a set of security criteria. The universal security manager may provide the EMR information from an EMR system associated with the healthcare service facility to the trusted third-party application based on a set of permissions created and/or maintained by a user.
The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
1. Use an infusion set equipped with a low-protein-binding, 0.2 micron, in-line filter to administer the diluted ALDURAZYME solution.
  2. The total volume of infusion [see Dosage and Administration (2.2)] should be administered over approximately 3 to 4 hours as tolerated per the infusion rate steps outlined in Table 1 below.
  3. At the end of the infusion, flush the infusion line with 0.9% Sodium Chloride Injection, using the same infusion rate as the one used for the last part of the infusion.
  4. Do not infuse ALDURAZYME in the same intravenous line with other products.



Start infusion at rate in Step 1. In the absence of infusion-associated reactions after vital sign assessment, increase infusion rate sequentially per the steps in Table 1 every 15 minutes to reach the target rate in Step 5. Continue Step 5 until infusion is completed. The total infusion time is approximately 3 to 4 hours.
Hypoxic-ischemic encephalopathy of the newborn infant remains a significant socio-economic health problem worldwide. Moderate to severe HIE of newborn infants is associated with a high rate of death or long-term disabilities. Historically, treatment has been purely supportive including stabilizing cardio-respiratory functions and treating convulsions.Recent multi-center trials assessing the effects of hypothermia demonstrated improved outcome in term neonates with moderate hypoxic-ischemic encephalopathy (HIE). However, hypothermia was not effective beyond 6 hrs after brain injury.

Systemically administered EPO was neuroprotective in neonatal brain injury models. Clinical study on adult stroke showed improved outcome. However, treating HIE with EPO raises a series of questions such as: i) Can the patient population of this study readily be compared with those in the hypothermia trials? ii) What are the pharmacokinetics of EPO, including issues of dosage and timing, and does administered EPO cross the blood-brain-barrier? iii) How does the effectiveness, side effects and potentials of EPO therapy compare with induced hypothermia?